Kyverna Therapeutics, Inc.
mivocabtagene autoleucel
generalized myasthenia gravis
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for mivocabtagene autoleucel in generalized myasthenia gravis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Kyverna is progressing its FDA-aligned Phase 3 gMG clinical trial.”